Respiratory Syncytial Virus

nanobio

Ann Arbor Firm’s Technology Makes Vaccines More Effective

NanoBio Corp. Tuesday said that it is presenting new data demonstrating positive pre-clinical results for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.

WWJ Newsradio 950–04/23/2013

nanobio

NanoBio To Report Data On New RSV Vaccine At Symposium

NanoBio Corp. announced Monday it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus Symposium taking place Sept. 27-30 in Santa Fe, N.M.

WWJ Newsradio 950–09/24/2012

nanobio

NanoBio To Present Data On RSV Vaccine

NanoBio Corp. said it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting this week in San Francisco.

WWJ Newsradio 950–09/10/2012

nanobio

NanoBio In RSV Vaccine Research Effort With Merck

Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).

WWJ Newsradio 950–12/08/2011

nanobio

NanoBio’s Intranasal Vaccine Induces Robust Immunity in Animals

NanoBio Corp. announced Wednesday that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus vaccine have shown strong immunity effects, paving the way for more studies of the nanoparticle-based technology.

WWJ Newsradio 950–08/24/2011

research

NanoBio Gets $6M Gates Grant For Nasal RSV Vaccine

Ann Arbor-based NanoBio Corporation announced Tuesday that it has received a $6 million grant from the Bill & Melinda Gates Foundation to support development of an intranasal vaccine for Respiratory Syncytial Virus.

11/30/2010

Follow

Get every new post delivered to your Inbox.

Join 1,972 other followers